News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|February 26, 2024

NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

Ronald D. Alvarez, MD, MBA, discusses challenges in implementing updated NCCN guidelines, such as coverage limitations imposed by payers.

Episodes in this series

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"

EP. 2 NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 3 Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 4 MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 5 Tailored Therapy: Decision Making for Ovarian Cancer Treatment

Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"

EP. 6 Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"

EP. 7 Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Keith Bellovich, Do, MBA

CKM Guideline Aims to Break Down Specialty Silos: Keith Bellovich, DO

ByGiuliana Grossi,Keith Bellovich, DO, MBA

September 3rd 2026

Drs Jeff Romine and Kofi Essel

Grocery Assistance Shows Potential in Diabetes Care and Beyond

ByBrooke McCormick,Jeff Romine, PhD,Kofi Essel, MD, MPH

Published: September 3rd 2026 | Updated: September 3rd 2026

From the Exam Room to the Formulary: Access Challenges in Adjunctive MDD Therapy

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 3rd 2026

2 experts are featured in this video

Rethinking Standard of Care and the Promise of Functional Cure

ByRaymond Chung, MD,Douglas Dieterich, MD

September 3rd 2026

Unmet Needs and Mechanisms: Understanding Adjunctive Antipsychotics in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 3rd 2026

Trending on AJMC

Multiagonists Outpace Older GLP-1 Drugs for Weight Loss

How Long-Acting Injectables Are Changing HIV Care

Less-Intensive Leukemia Regimen Outperforms Standard Chemo

Evolocumab Cuts Death Risk for a First Heart Attack or Stroke

Inside Myeloma’s Evolution From Death Sentence to Cure